accountNEW YORK, Oct 29 (Reuters) - Shares of Transcept Pharmaceuticals Inc (TSPT.O) plunged 46 percent to $6.25 in premarket trading on Thursday after the company said the Food and Drug Administration rejected its experimental sleep disorder drug. For...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to BEFORE THE BELL-Transcept Pharma sinks after drug rejected
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
